Vanda's Imsidolimab Gets EU Orphan Drug Status for Rare Skin Disease
VNDA sits 34% above its 52-week low of $4.14.
Summary
The EMA's orphan drug designation for imsidolimab in generalized pustular psoriasis (GPP) is a first for any GPP treatment in the EU, providing market exclusivity and regulatory incentives. This follows the recent FDA Rare Pediatric Disease Designation for VCA-894A, building a pattern of regulatory progress. The designation validates the clinical data and could accelerate the path to market in a disease with high unmet need. With shares down 38% this year and the company burning cash, positive regulatory news is a welcome development.
At the time of this announcement, VNDA was trading at $5.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $327.7M. The 52-week trading range was $4.14 to $9.94. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.